During the past decade, both in vitro and in vivo studies have provided new insights into the cellular and molecular mechanisms that govern angiogenesis and arteriogenesis. However, therapeutic angiogenesis clinical trials using recombinant protein or gene therapy formulations of single angiogenic growth factors have yielded at best only modest success to date. Among the second generation of angiogenic agents are therapeutic transgenes that enhance expression of two or more proangiogenic cytokines. These include synthetic constructs that mimic that activity of endogenous transcriptional regulators and other upstream, regulatory factors that have the potential to induce formation of morphologically and physiologically functional vessels. These agents are now beginning to be evaluated in clinical trials for patients with advanced ischemic cardiac and peripheral vascular disease.
Introduction
Individuals with symptomatic manifestations of atherosclerosis, including coronary artery disease (CAD) and peripheral arterial disease (PAD), are currently treated with drugs, such as HMG CoA reductase inhibitors ('statins'), vasodilators and antiplatelet agents. As their disease progresses, patients require invasive vascular procedures, which include surgical interventions, such as coronary artery bypass grafting (CABG), or percutaneous, catheter-based interventions (PCI), including angioplasty and intravascular implantation of metallic scaffolds ('stents'), some of which now are impregnated with drugs that prevent vascular smooth muscle proliferation. [1] [2] [3] [4] [5] Nevertheless, many subjects with advanced atherosclerosis are not suitable candidates for initial ('primary') or repeated PCI or surgical procedures, and therefore are often referred to as 'no option' or 'few option' patients. This has been particularly problematic in patients with advanced PAD, termed 'critical limb ischemia' (CLI). Other than risk factor modification, current treatments such as the use of platelet inhibitors, statins and angiotensin converting enzyme (ACE) inhibitors among other agents, have had limited impact on the outcome of advanced lower extremity PAD or CLI, often leaving revascularization as the only possible option with reasonable short-term results, albeit limited long-term efficacy. If surgical procedures are contraindicated, PCI with or without stent placement, often results in less than a durable improvement in blood flow. [6] [7] [8] [9] [10] In brief
Progress
Many of the signaling pathways that contribute to angiogenesis and arteriogenesis are increasingly well understood. Nevertheless, clinical trials of proangiogenic agents employing a single angiogenic cytokine, despite efficacy in experimental animal models, have had only modest success at best in clinical trials to date. Despite a lack of durable efficacy to date, the safety of single angiogenic agents has been reassuring, albeit based on a relatively small but growing database of exposed patients. Our increasing understanding of the molecular pharmacology of angiogenesis indicates that formation of normal vessels will likely require the orchestration of a number of endothelial growth factors, their receptors and extracellular matrix proteins.
Advances in our understanding of proangiogenic signaling pathways
The molecular pharmacological and cellular mechanisms that contribute to new blood vessel development are gradually being elucidated. These processes include vasculogenesis, which describes formation of the vascular tree during development occurring via recruitment and differentiation of progenitor cells; angiogenesis, which refers to the development of the microvasculature, including the sprouting of new capillaries and venules from existing small blood vessels; arteriogenesis, the growth and remodeling of existing arterioles into larger arteries and conduit vessels. [11] [12] [13] [14] Following development, of the known growth factors that stimulate angiogenesis, members of the vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF) and monocyte chemoattractant protein-1 families of angiogenic cytokines, among others, are capable of inducing recruitment, mobilization, proliferation and homing of endothelial progenitor cells ('EPCs') and pericyte precursors. In relatively young, healthy animals typical of those used for most proof-ofconcept experimental angiogenesis protocols, the response to ischemia results in formation of 'collateral vessels,' that is the generation of fully functional, mature vessels, of sufficient caliber to restore blood flow to tissues. [15] [16] [17] [18] [19] [20] [21] In contrast, in older, diseased animals -as in older, diseased patients -this process is delayed or truncated for reasons that remain incompletely understood. Ho et al., 21 for example, have demonstrated that endogenous levels of the hypoxia-induced transcription factor hypoxia-inducible factor-1a (HIF-1a), are increased in tissue taken from the lower limbs of patients with advanced CLI, but this physiologic response is clearly insufficient and/or dysfunctional with regard to the restoration of blood flow necessary to prevent further tissue loss in many if not most patients.
Trials of single proangiogenic agents have had modest benefit to date
Unfortunately, clinical trials using either a single angiogenic protein or gene therapy have yielded only modest success to date, despite promising data in small animal and selected large animal models. With the benefit of hindsight, possible explanations for the lack of evidence of clinical efficacy include both difficulty in targeting angiogenic proteins or genes to sites of ischemic but viable tissue, and the relatively short pharmacological half-lives of these agents (particularly the recombinant protein formulations of proangiogenic cytokines). Indeed, it is likely that sustained bioactivity for days or perhaps weeks may be necessary to induce durable vessel formation, growth and remodeling. It is also now recognized that an additional source of confounding in the first generation of angiogenesis studies -whether delivered as a protein or a therapeutic transgene -was the fact that all patients in investigational studies receive improved medical care, including more frequent clinical follow-up, simply by enrolling in a clinical trial. This typically involves more frequent visits to a physician or study nurse, during which all participants -both placebo and actively treated patients -are queried regarding pill counts for drugs known to be beneficial in these patients, such as statins, antihypertensive and antiplatelet agents.
Patients may be encouraged to initiate graded exercise programs, and receive dietary advice and wound care if appropriate. Any of these strategies may shift the patient to a new baseline level of activity, and possibly slow disease progression. This is an obvious source of concern if an appropriate run-in period is not provided in the design of each trial, since the clinical study may be underpowered to demonstrate a statistically significant treatment effect.
Gene-based formulations of angiogenic agents were approved for clinical trials several years later than the initial recombinant protein angiogenesis trials. The first agents studied utilized plasmid vectors encoding VEGF-A 165 or acidic FGF (phFGF-1) in patients with refractory CAD and PAD. [22] [23] [24] [25] [26] [27] [28] [29] [30] . Among the largest PAD genetherapy clinical trials to date, was the RAVE study, a Phase 2 randomized, double-blind, placebo-controlled clinical study of Ad/VEGF-A 121 in 107 subjects with unilateral, advanced intermittent claudication. Both placebo and actively treated cohorts demonstrated improvement in the primary end point of peak walking time (PWT) on treadmill testing at 12 weeks, but there was no significant difference between the treated and control groups.
Although disappointing with regard to efficacy, there were no major safety issues associated with Ad/VEGF-A 121 administration through 1 year of follow-up, suggesting that angiogenic gene therapy, at least with VEGF-A 121 when delivered in an adenoviral vector, (i.e., with relatively short-term gene expression) appeared to be safe. 31 'Multivalent approaches': combinations of angiogenic cytokines or use of transcription factors for therapeutic angiogenesis Strategies that utilize a combination of two or more angiogenic cytokines that target multiple proangiogenic pathways have now reached clinical trials, based on safety and efficacy demonstrated in experimental animals. The rationale for combining cytokines that activate different but complementary pathways was illustrated, for example, in transgenic mouse models overexpressing both VEGF-A 164 and angiopoietin-1 in the skin. Vessels were produced that were resistant to edema formation demonstrating, not surprisingly, that formation of normal vessels requires the orchestration of a number of angiogenic cytokine and extracellular matrix proteins (reviewed by Tirziu and Simons 30 ). Similar data have been reported by Zheng et al., 32 who employed a chimeric VEGF-E(N7Z)/ PlGF transgene, (i.e., a transgene that expressed both a VEGF-E isoform as well as placental growth factor). When expressed in mice, the hybrid transgene exhibited little evidence of excessive edema or inflammation, unlike that seen with sustained expression of some VEGF-A isoforms.
Another example of a 'multivalent' angiogenic approach is the use of HGF, which has been documented to induce a coordinated proangiogenic response, both in vitro and in vivo, via signaling through its receptor cmet. 33 Phase I safety and bioactivity studies of plasmid formulations of human HGF driven by a cytomegalovirus (CMV) promoter in patients with either Buerger's disease (a form of systemic arteritis leading to limb ischemia that is typically seen in relatively young adults) or CLI, reported in the spring of 2006, provided 
HIF-1a
The use of constitutively active formulations of a HIF-1a, a heterodimeric, basic, helix-loop-helix-PAS domain transcription factor, [35] [36] [37] provides another example of an approach aimed at inducing a neovasculature that is resistant to perivascular edema formation. HIF-1 is composed of two subunits, HIF-1a and HIF-1b (the latter also termed 'aryl hydrocarbon nuclear translocator,' or 'ARNT'). The stability of the a subunit of HIF-1, and thus its transcriptional activity, is precisely controlled by the intracellular oxygen concentration. Compared with VEGF-A transgenic mice, noted above, expression of a constitutively active HIF-1 construct in murine skin resulted in increased neovascularization without excessive permeability leading to tissue edema (ref) . Localized delivery of a constitutively active HIF-1a formulation has also been shown to accelerate dermal wound healing at a rate equivalent to that of a VEGF-A-positive control reagent, but with enhanced maturity of the resulting wound-bed microvasculature (i.e., the rate of smooth muscle association with endothelial cells in newly formed vessels). 38 Expression of stable, constitutively active hybrid formulations of HIF-1a, have resulted in induction of a number of hypoxia-responsive genes, including several VEGF-A isoforms, angiopoietin/Tie-2, PlGF and other proangiogenic pathways ( Figure 1) . 25, 39 Recently, HIF-1a has also been shown to induce expression of stromal cell-derived factor 1 (SDF-1), which is known to facilitate homing of circulating EPCs. 16, 39, 40 A recent review by Ceradini and Gurtner 41 highlights the role of hypoxic gradients in EPC biology, as well the regulation of SDF-1 and its principal receptor, CXCR4, each of which has also been implicated in vascular remodeling and induction of arteriogenesis, in part due to activation of both HIF-1 and PI3K/PTEN/AKT/mTOR signaling. 42 Parenthetically, it is of interest that Semenza and his collaborators 43 have shown that activation of PI3K/AKT/ mTOR in some cell types also leads to increased HIF-1a expression and activity, an effect that appears to be enhanced by muscarinic cholinergic signaling. In addition, Grunewald et al. 44 have also noted the role of angiogenic cytokine release in the induction, recruitment and retention of non-EPC, bone marrow-derived progenitor cells due principally to increased expression of VEGF and SDF-1, both of which are HIF-1a dependent.
In a rabbit ischemic hindlimb model, plasmid DNA encoding a constitutively active HIF-1a hybrid gene was at least as effective as treatment with human phVEGF-A 165 . Increased blood flow to the affected limb was measured by the number of angiographically visible collateral arteries (i.e., arteries 4200 mm diameter) and by enhanced vascularity at the capillary level in histological sections. Microscopic areas of dose-dependent inflammation at the sites of injection of the therapeutic transgene were also apparent, supporting the hypothesis that inflammation may be a common, if not essential, component of the angiogenic process. 25 These observations are consistent with the report of Pajusola et al., 45 who used an adeno-associated virus (AAV) vector, which permits relatively sustained expression of a therapeutic transgene when compared, for example, with adenoviral or plasmid vectors. AAV-mediated expression of the stabilized HIF-1a mutants increased capillary sprouting, endothelial cell proliferation and, eventually, perfusion to a greater extent than either AAV/VEGF-A 164 or AAV/VEGF-A 120 alone. Similarly, Heinl-Green et al. 46 employed a porcine model of myocardial ischemia and documented that direct intramyocardial injection of Ad2/HIF-1a/ viral particles (VP)16 resulted in a significant improvement in myocardial perfusion during stress, as measured by tissue microsphere entrapment and enhanced left ventricular function compared with control animals, suggesting recovery of ischemic but hypo-functioning areas of myocardium. These investigators could find no detectable difference in collateral vessel development, however, as quantified by Rentrop (angiographic) scoring, suggesting either that the increase in myocardial perfusion was owing to new vessels of smaller caliber than could be resolved by coronary angiography or through other as yet unknown mechanisms. An additional possibility has been suggested by Luo et al., 47 who demonstrated the induction of B-type natriuretic peptide (BNP) by HIF-1a, providing documentation of a hypoxia response element within the BNP promoter. Given the association of natriuretic peptides with proangiogenic activity in several tissues, among other moderately beneficial effects of constitutive, low levels of BNP on the failing myocardium, the induction of BNP by HIF-1a may confer a net beneficial effect, although this remains a hypothetical advantage based on currently available information. 48 Kido et al. 49 have reported results similar to those of Heinl-Green et al., discussed above, using a constitutively active construct of HIF-1a driven by a aMHC promoter in transgenic mice. In a murine infarct model, animals expressing the active HIF-1a construct had improved conservation of left ventricular muscle and significantly 50 have also demonstrated that either of two constitutively active HIF-1a constructs -that is with either a Herpes virus VP16 or nuclear factor kappa B (NF-kB) transactivation domain -when expressed in neonatal ventricular myocytes, protected equally well against ischemia reperfusion injury in vitro.
An alternative approach was developed by Natarajan et al., 51 who, rather than utilizing a constitutively active HIF-1 construct, attenuated the activities of the HIF-1 prolylhydroxylases (PHDs). Using small interfering RNA targeting the expression of PHD-2, these investigators demonstrated that this approach could not only activate HIF-1 signaling in vitro, but also rescue a large amount of cardiac muscle at risk in a murine global ischemia model in vivo, providing proof of concept that indirect activation of HIF-1a signaling was not only possible but also effective. Similar results have also been reported by Siddiq et al., 52 who described the rationale for, and effectiveness of, small molecule antagonists of PHDs in preventing ischemic injury via activation of HIF-1a signaling in the central nervous system. Interestingly, loss-of-function mutants of the tumorassociated protein OS-9, also have been shown to enhance HIF-1a activity by preventing its association with PHDs. [53] [54] [55] A number of small molecule inhibitors have recently been developed, which suppress physiologic responses, thereby mimicking the effect of activated HIF-1a (for a review of small molecule inhibitors of HIF-1a, see Diaz-Gonzalez et al.
56
). For the purposes of tracking physiologic HIF-1 activation and deactivation in real time, Safran et al.
57 generated a transgenic mouse that expresses a bioluminescent marker, firefly luciferase, fused to a HIF1a promoter construct, thus providing a tool to track in real time the kinetics of HIF-1a inhibition in response to, for example, small molecule PHD inhibitors.
Cell-type selective deletion of HIF-1a in murine cardiac myocytes has recently been demonstrated by Huang et al. 58 to result in diminished proangiogenic and myocardial contractile responses at rest and during hypoxic stress, as well as a decrease in myocardial lactate production, thus highlighting the role of HIF in the regulation of energy metabolism when oxygen is limiting. The physiologic consequences of hypoxia-induced HIF-1a activation on the tricarboxylic acid cycle have recently been clarified by Kim et al., 59 particularly with regard to the regulation of programmed cell death. They demonstrated the importance of HIF-1a activation in increasing pyruvate dehydrogenase expression and activity, thereby promoting maintenance of intracellular ATP levels and minimizing induction of apoptosis owing to substrate depletion during hypoxic stress. Other HIF-1 isoforms, such as endothelial PAS domain protein 1, or 'HIF-2a,' have also been shown to induce a number of proangiogenic pathways that are similar to those characteristic of HIF-1a signaling. 60 
HIF-1a, inflammation and induction of arteriogenesis
The report from the Johnson laboratory in 2003 linking HIF-1a with a number of 'proinflammatory' signaling cascades has engendered a number of publications probing the links between HIF-1a signaling, activation of the innate immune response, and the induction of angiogenesis and arteriogenesis.
27,61-67 For example, HIF-1a has been implicated to date in the pathogenesis of bacillary angiomatosis, 68 induction of cytokines such as interleukin-1 69 and genes such as CD55, which promote neutrophil clearance. 70 Indeed, even T-cell receptor signal transduction appears to be in part HIF1a dependent. 71 In lymphocytes, as in other cell types, HIF-1a activation indirectly affects intracellular calcium signaling, in part by regulating Serca2 expression and activity. These data suggest a role for HIF-1 and perhaps other HIF isoforms, in shaping or managing the T-cell repertoire under certain conditions, possibly by promoting the selective induction of apoptosis in subsets of T cells. HIF-1a is also well known to regulate several proapoptotic intracellular signaling pathways, such as activation of BNIP3, among other mechanisms, thereby facilitating HIF-1-induced apoptosis in specific cell types when metabolic substrates are limiting. 72 While a role for the activation of selected proinflammatory pathways in the process of angiogenesis and arteriogenesis -a number of which are now known to be in part HIF-1a dependent -is well established, initial clinical trials of cytokines associated with inflammation have not yet demonstrated durable new blood vessel growth. For example, the recently reported results of the START trial, 73 in which granulocyte-macrophage colony stimulating factor (rhGM-CSF) was injected into peripheral vascular disease patients over a 14-day period, demonstrated no difference between actively treated and control patients in peak walking distance, the primary end point of the study. This was despite significant increases in blood GM-CSF and C-Reactive Protein (CRP) levels in the actively treated subjects when compared with controls. As noted above, however, with regard to angiogenesis gene therapy clinical trials, the lack of efficacy may have been due, at least in part, to the relatively rapid clearance of the recombinant protein formulation of GM-CSF.
Clinical trial experience with constitutively active HIF-1a mutants
An adenoviral formulation of a constitutively active HIF-1a construct, Ad2/HIF-1a/VP16, has been studied in Phase I dose escalation safety studies in two patient populations: (1) patients with 'no option' CLI (i.e., patients with rest pain/and or tissue necrosis who no longer were suitable for further standard revascularization procedures) and (2) patients with advanced CAD who received injections at CABG surgery into an area of cardiac muscle that could not be revascularized for technical reasons. The results of these Phase 1 studies, which are under review as of this writing, showed that Ad2/HIF-1a/VP16 appeared to be well tolerated at doses ranging from 1 Â 10 8 up to 2 Â 10 11 VP. A Phase 2, placebo-controlled, randomized clinical trial, coined the 'walk' trial, is currently ongoing in patients with advanced intermittent claudication (i.e., a PWT of less than 10 min in patients who are refractory to existing drug or surgical/percutaneous therapeutic interventions), with 2 Â 10 11 VP of Ad2/HIF-1a/VP16 as the highest dose. Trial results are tentatively expected in 2008.
PR39
PR39 is a proline and arginine-rich peptide that induces angiogenesis indirectly by relatively selectively inhibit- 74, 76 Delivered in an adenoviral vector, PR39 would be expected to induce a pattern of angiogenesis signaling pathways similar to constitutively active formulations of HIF-1a, although no direct comparisons of these two proangiogenic constructs in vivo have been published to date. In a recent study, Ad/PR39 was co-administered with a HIF-1a-dominant negative (dn) construct in a mouse model of ischemia-reperfusion injury. Co-transfection of PR39 with the HIF-1a-dn construct abrogated the cardioprotective effect of PR39, demonstrating that this effect was indeed dependent upon HIF-1a-dependent signaling. 75 
RTEF-1
While activation of HIF-1a isoforms in cells undergoing hypoxic stress is well described, there is emerging evidence for additional hypoxia-triggered signaling pathways. Related transcriptional enhancer factor-1 (RTEF-1), for example, a member of the TEF-1 family of enhancers present in many genes, is robustly expressed in both cardiac and skeletal muscle, among other tissues. Increased expression of RTEF-1 is induced by hypoxia in endothelial cells, and RTEF-1 overexpression drives VEGF-A promoter activity via interactions with Sp1 response elements, indicating possible synergistic activation of the VEGF-A promoter with other hypoxia-directed transcriptional regulators. 77 
c-Myc
Recent data reported by Mizukami et al. 78 point to a portion of the VEGF-A promoter that appears to be responsive to hypoxia in a PI3K/Rho/ROCK-dependent manner (i.e., as determined by its sensitivity to the PI3K inhibitor LY294002 or appropriate dominant negative constructs to these signaling intermediates). This alternative mechanism for VEGF-A induction appears to involve a c-Myc-dependent pathway, apparently providing another layer of redundancy in promoting VEGFinduced angiogenesis in addition to the HIF1a-dependent pathways described above.
Notch signaling
The recent identification of links among canonical Notch signaling pathways and the regulation of angiogenesis, particularly in the maturation phase of new blood vessel development, has uncovered another layer of complexity with regard to our understanding of blood vessel formation. The link between Notch and angiogenesis, as described by Gustafsson and colleagues, 79 appears to be the association of the Notch intracellular domain (NIC) with HIF-1a, forming a heterodimer that suppresses expression of at least several HIF-dependent signaling cascades, including activation of PKG1 among others. As summarized by Sainson and Harris, 80 one hypothesis is that increased Notch signaling in endothelial cells suppresses angiogenesis, thereby permitting maturation of newly formed vessels, although the specific molecular mechanisms remain to be defined. Gustafsson et al. 79 have also demonstrated that Notch upregulates other angiogenesisrelated target genes, such as HES-1 and HEY-2. Thus, it is possible that Notch activity may play an enabling role in blood vessel maturation and subsequent arteriogenesis.
JAK/STAT signaling
Signal transducers and activator of transcription (STATs), and members of the Janus kinases (JAKs), are nearly universal intracellular signaling proteins that mediate multiple functions in the heart as well as all other organs (see references 81, 82 for recent reviews). Drexler and colleagues have shown that STAT-3 activity plays an essential role in regulating cardiac function after development, in part owing to its role in increasing capillary density. 83 More recently this group has developed conditional, cardiac-restricted targeted deletion of JunD, an AP-1 transcription factor, in the murine heart. 84 These animals were viable at birth, but rapidly developed a dilated cardiomyopathy, due in large part to diminished capillary density despite the presence of a hypoxic tissue environment (indeed, endogenous HIF-1a signaling was enhanced, apparently appropriately, in this model). Unsurprisingly, these cardiac-restricted JunD null animals also developed progressive ventricular fibrosis, and experienced premature mortality. The specific mechanisms that contributed to myocyte drop out and progressive contractile dysfunction, remain to be defined. Nevertheless, these data suggest that expression of STAT-3 signaling appears to be essential and non-redundant with other transcriptional regulators for the growth, maintenance and repair of the postnatal microvasculature.
TFII-1 and related signaling factors
A large number of transcriptional regulatory strategies in addition to those described above, have evolved to control the development of new blood vessel formation (for a recent overview of the known transcription factors involved in blood vessel formation during development, see Bhattacharya et al). 85 Among the more common elements driving or restricting angiogenesis is the TF-II family, including TFII-1, which binds to Inr (Initiator) elements in the VEGFR-2 promoter, among other genes. TFII-1 is unusual in that it exhibits transcriptional activity both via Inr, as well as at upstream promoter sequences. 86 Interestingly, a related isoform of TFII-1, known as 'TFII-1IRD1,' appears to act as a counterregulatory signaling mechanism, due at least in part to a direct interaction between TFII-1 and TFII-1RD. In addition, at least one histone deacetylase (HDAC3), also appears to act as a brake on TFII-1 activity, as nonspecific HDAC inhibitors reverse the suppression of angiogenesis owing to TFII-1RD in vitro.
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Engineered zinc-finger transcription factors and angiogenesis
Among the most tractable of the molecular strategies that have been developed to date for the formulation of artificial transcription factors has been the use of zinc finger protein (ZFP) transcription factors (see reference 86 for a recent review). Engineered ZFP constructs bind to specific gene sequences in promoter regions of target Therapeutic angiogenesis for ischemic cardiovascular disease KA Vincent et al genes, although both their specificity and degree of gene induction are modified in part by the chromatin environment. One of several advantages of these constructs is the fact that ZFPs can engage in both RNA and protein interactions. Thus, 'effector domains,' such as the VP16 transactivation domain of herpes virus, or the transactivation domain of NF-kB, among many others, can be used to facilitate robust transcription of target genes using ZFP constructs. However, the specificity of induction of target genes will remain an important safety concern, pending the acquisition of more experimental animal and, eventually of course, human safety data.
In the context of angiogenesis, the use of ZFPs has been pioneered by Giordano and colleagues ( 87 and references therein, and by Annex and his collaborators 88 and Xie et al. 89 ). In a murine femoral ligation model of peripheral vascular disease in aged mice, administration of a adenoviral formulation of an engineered, VEGF-A zinc-finger transcription factor (ZFP MVZ+426b)-induced supraphysiologic tissue levels of multiple splice variants of the murine VEGF-A gene, associated with improved function of the affected limb. 87 Blood flow was enhanced, with progressive improvement over time. Interestingly, a number of genes other than the VEGF-A isoforms were also induced, including FGF-1, IGF-1, PDGF-B, PlGF and osteopontin, among other genes associated with angiogenesis, all of which may have contributed to the improvement in limb salvage.
Annex and his collaborators, for example, had reported positive results in 2004 in a rabbit femoral ligation model, using a plasmid formulation of a zinc-finger transcription factor that induced multiple VEGF-A isoforms. 88 In a more recent publication, 89 this group compared viral and nonviral (plasmid) formulations of a zinc-finger construct (ZFP-32E) that induced all the major VEGF-A isoforms in ApoE deficient, hypercholesterolemic mice (n ¼ 117), when administered 7 days following femoral artery occlusion (i.e., controls received injections of one of three agents: a null plasmid, a plasmid encoding b-galactosidase or an adenovirus with a b-galactosidase transgene). Ischemic animals that received the ZFP-32E construct, had, as expected, significantly higher VEGF-A mRNA and protein levels, a higher capillary density and lower rates of apoptosis in the affected limb, along with significantly improved blood flow at 21 days. Although the number of animals in each group was relatively limited, these data generated in a relatively robust experimental model of atherogenesis, provides additional evidence that therapeutic arteriogenesis is both possible and effective -at least in a relevant small animal model of human disease.
Early growth response gene-1
There are of course many other transcription factors that impact both angiogenesis and arteriogenesis. Early growth response gene-1 (Egr-1), for example, an immediate early gene encoding a zinc-finger transcription factor, has been demonstrated to play several roles in inducing new blood vessel growth following development. As noted recently by Lucerna and colleagues 90 and by Khachigian, 91 sustained Egr-1 expression and subsequent angiogenesis leads eventually to suppression of new vessel development and/or growth, due in part to Egr-1-dependent induction of the co-repressor NAB2. Indeed, these investigators have demonstrated that this approach suppresses growth of fibrosarcomas in mice, in part by NAB2-dependent decreases in angiogenic responsiveness.
Among the factors that initiate Egr-1 signaling is HGF. As noted above, HGF signaling via c-met induces angiogenesis via several complementary pathways, including Egr-1-mediated induction of PDGF-A and VEGF-A genes, among other pathways that are important to vascular growth and maturation. 92 EGR-1 has been demonstrated to play a direct role in both angiogenesis and arteriogenesis -the 'remodeling' of small, usually preexisting arterioles, into larger vessels as described above -a process facilitated by a variety of proinflammatory pathways. 65, 93 Perhaps the most persuasive evidence to date of the essential role of EGR-1 signaling in the successful induction of an angiogenic response is that of Sarateanu and colleagues, who used mice with targeted deletion of Egr-1. 94 These animals were viable but, among other phenotypic changes, had a substantially reduced ability to mount an angiogenic response in response to, for example, hindlimb ischemia induced by femoral artery ligation. Adenoviral delivery of a CMV promoter-driven EGR-1 construct, into muscle adjacent to a femoral artery ligation, resulted in both angiogenesis and arteriogenesis (the latter as defined by the number vascular smooth muscle actin-positive cells in vessels larger than 50 mm in microscopic sections). Interestingly, the total number of capillaries in the ischemic territory was not significantly different between the Egr-1 null and wild-type animals, suggesting a relatively selective arteriogenic response in this disease model. 94 
ETS-1 transcriptional regulators
The ets family of transcriptional regulators mediate both the induction and the extent of neoangiogenesis, in large part owing to their role in regulating the transcription of proteases that are essential for induction of capillary, venular and, eventually, arteriolar remodeling and growth during development. 95 In a murine hindlimb ischemia model, overexpression of E26 transformation-specific sequence-1 (ETS-1), when delivered in HVJ liposomes (plasmid delivery was determined to be ineffective, at least in this model), resulted in significant increases in capillary density and in collateral blood vessel formation. It should be noted that there are ETS-1 binding sites in the promoter regions of both the HGF and VEGF-A genes, among others associated with angiogenesis. Indeed, Hashiya et al. 96 have provided data for a positive feedback loop, in which activation of HGF and VEGF-A by ETS-1, resulted in further increases in ETS-1 transcriptional activity.
Homeobox transcriptional regulators and angiogenesis
Although more commonly associated with development, postnatal expression of homeobox (HOX) genes impacts many aspects of normal and pathologic molecular physiology. With regard to angiogenesis, HOXA3 in particular has been demonstrated to play a pivotal role in wound repair, largely owing to its role in promoting angiogenesis (reviewed by Martin and Parkhurst 97 ). Mace and colleagues 98 , for example, have shown that endothelial cells, which typically exhibit relatively low levels of HOXA3, increase expression of this transcriptional Therapeutic angiogenesis for ischemic cardiovascular disease KA Vincent et al activator rapidly after injury in dermal wound models. This results in upregulation of specific matrix metalloproteinases (MMPs) that promote wound repair, for example, keratinocytes, in part by facilitating endothelial cell migration and subsequent neovascularization.
Safety issues relevant to angiogenesis gene therapy
As with any new medical technology, there are always a number of safety concerns, both established and theoretical, regarding either local or systemic administration of a novel therapeutic agent. Among these are questions regarding mechanisms by which proangiogenic agents, whether delivered as recombinant proteins or as genes, could enhance the blood supply to occult tumors, thereby promoting their growth. To test this hypothesis, using a subcutaneous neuroblastoma model, intracardiac injections into nude rats of a constitutively active HIF-1a construct (i.e., Ad2/HIF-1a/VP16), at doses currently being used in humans (e.g., 10 10 VP), had no effect on tumor growth, while a positive control, a high dose of a recombinant VEGF preparation (rhVEGF-A 165 given at 6.7 mg/rat/daily IV for 3 days) did accelerate tumor enlargement (Genzyme Corporation, unpublished data). These results are consistent with a study by Matsuki et al., 99 who noted similar findings with a plasmid formulation of human HGF. Following intramuscular injection of HGF into the hindlimb of BALB/c nu/nu mice (i.e., modeling the drug delivery paradigm as would be the case in the treatment of peripheral vascular disease, for example), there was no detectable acceleration of growth in subcutaneously injected A431 human epidermoid tumor cells when compared with control. One implication of these data is that there may be a threshold effect, in which local delivery of angiogenic cytokines to ischemic tissue may not impact occult tumor growth systemically, at least up to a threshold concentration. These data notwithstanding, until a substantially larger safety database is available, information from current and planned angiogenesis gene therapy protocols will continue to be carefully scrutinized for evidence of acceleration of growth of preexisting, occult tumors.
Prospects
Angiogenesis gene therapy has yet to deliver on its initial promise of providing an adequate response to tissue ischemia in humans with advanced ischemic vascular disease. Second generation formulations that induce, for example, multiple VEGF-A isoforms, as well as other proangiogenic signaling proteins, such as constitutively active HIF-1a constructs, among others, are now entering Phase II clinical trials. The design of these therapeutic agents is predicated on the recognition that complimentary and/or synergistic interactions involving multiple signaling cascades are probably necessary to induce physiologically relevant improvements in blood flow to areas of refractory tissue ischemia. Whether these, or any other, proangiogenic agents will ultimately be found to be both effective and exhibit an acceptable risk-benefit profile will require continued diligence, provision of adequate resources and patience among both patients and clinical investigators alike.
